Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis
Authors' conclusion
The TyG index is a simple new synthetic index that has been proven to be a valuable tool in the whole-course management of CAD patients. Patients with higher TyG index levels are at a higher risk of CAD, more severe coronary artery lesions, and worse prognosis compared to those with lower TyG index levels.
Study context
- Population
- Patients with coronary artery disease (CAD); PubMed, EMBASE, Cochrane Library and Web of Science searched from inception to May 1, 202341 studies
- Comparison
- Highest vs lowest TyG index
- Outcome
- MACE (CAD prognosis)
Methodological detailscross-sectional and retrospective or prospective cohort studies
- Cross-sectional and retrospective or prospective cohort studies
Pooled result
As reported in the abstract
MACE, TyG index as categorized variable
Highest TyG index vs Lowest TyG indexHazard ratio (95% CI)P value
ACS patients; I2 = 87%
2.09(1.68–2.62)
P < 0.00001CCS or stable CAD patients; I2 = 85%; trend
1.24(0.96–1.60)
P = 0.09- Major adverse cardiovascular events (MACE), acute coronary syndrome (ACS): HR per 1-unit/1-SD increment of TyG index
- 2.28 (95% CI 1.44-3.63, I2 = 95%, P = 0.0005)
- MACE, chronic coronary syndrome (CCS) or stable CAD: HR per 1-unit/1-SD increment of TyG index
- 1.49 (95% CI 1.21-1.83, I2 = 75%, P = 0.0001)
- MACE, MI with non-obstructive coronary arteries: HR per 1-unit increment of TyG index
- 1.85 (95% CI 1.17-2.93, P = 0.008)
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| CAD riskI2 = 91% | 1.94 (1.20–3.14) | P = 0.007 | |
| Stenotic coronary arteriesI2 = 0% | 3.49 (1.71–7.12) | P = 0.0006 | |
| Plaque progressionI2 = 0% | 1.67 (1.28–2.19) | P = 0.002 | |
| Multi-vessel involvementI2 = 0% | 2.33 (1.59–3.42) | P < 0.0001 | |
| 0.10.31310Odds ratio (log scale) |
Original publication
Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →